LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Eli Lilly (LLY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, dominant position in the obesity drug market, positive analyst sentiment, and robust growth potential make it a compelling choice. While there are minor technical and insider selling concerns, the overall outlook remains positive for long-term gains.
The MACD is negative and contracting, RSI is neutral at 49.79, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1048.994, with support at 1002.994 and resistance at 1094.995. Overall, the technical indicators suggest a neutral to slightly bearish short-term outlook.
Strong Q4 financial performance with 42.56% YoY revenue growth and 50.48% YoY net income growth.
Dominant 60% market share in the weight-loss drug sector, outperforming competitors like Novo Nordisk.
Positive analyst sentiment with multiple price target upgrades, the highest being $1,
Congress trading data shows significant purchase transactions, indicating confidence in the stock.
Insider selling activity has increased by 4519.16% over the last month, which could indicate caution from company insiders.
Novo Nordisk's competitive moves in the weight-loss market could pose a challenge.
Technical indicators do not show a clear bullish trend in the short term.
Eli Lilly delivered a strong Q4 2025 performance with revenue increasing to $19.29B (up 42.56% YoY), net income rising to $6.64B (up 50.48% YoY), and EPS growing to 7.39 (up 51.43% YoY). Gross margin also improved slightly to 82.52%. These results highlight robust growth and operational efficiency.
Analyst sentiment is overwhelmingly positive, with multiple upgrades and price target increases. The highest price target is $1,300, reflecting confidence in Eli Lilly's leadership in the obesity market and its growth potential through 2026. Analysts emphasize the company's strong pipeline, GLP-1 market dominance, and upcoming product launches as key drivers of long-term growth.
